Coloplast stock gains as November guidance looms after nine-month 2026 update
Published on 08/24/2026 at 22:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Coloplast A/S (ISIN DK0060448595) stock is trading higher on August 24, 2026, after the Danish medtech company reiterated its earnings targets for fiscal 2025/26 following its nine-month 2026 update and investors began to focus on potential new guidance expected in November. Per recent analyst data dated August 24, 2026, the shares closed at 438.60DKK in the prior session and have been changing hands intraday around the mid-450DKK area on Cboe Europe, with a year-to-date decline of more than 16% despite a gain of more than 3% over the past five trading days. For investors, the combination of reaffirmed guidance and the prospect of an autumn update is now shaping the near-term story for Coloplast stock.
Analysts highlight November guidance as the next catalyst
Recent coverage on August 24, 2026, points out that the investment case for Coloplast has been strengthened by its latest operating performance while suggesting that new guidance expected in November could represent the next key catalyst for the shares. One analyst overview notes that the latest real-time estimate on Cboe Europe shows Coloplast trading at 456.55DKK, up 4.09% over the past five sessions and up 7.95% since the start of 2026, even though the stock remains down 16.45% year-to-date when measured against a longer comparison period. The same overview cites a prior closing price of 438.60DKK and an average target price of 467.10DKK, implying upside of 6.50% from that last close, with a maintained individual price target of 530DKK anchoring the bullish case. By comparison, consensus data compiled across 20 analysts shows an average recommendation in the hold range and an average target around 467.10DKK, underscoring that while some see more material upside, the broader market takes a more measured stance.
On secondary trading venues, the strength in Coloplast stock is also visible. An equity opinion overview for the London-listed line of Coloplast shows the shares quoted at 456.20DKK-equivalent, up 22.60 units or 5.21% at 09:08:36 local data time on August 24, 2026. A similar overview for the Xetra listing indicates a euro-denominated price of 60.90EUR, up 2.24EUR or 3.82% at 08:45:07, while a Tradegate snapshot shows Coloplast trading at 60.94EUR, a gain of 1.98EUR or 3.36% at 08:42:59. In Frankfurt, another opinion page records a price of 60.60EUR, up 2.04EUR or 3.48% at 07:21:09. These parallel moves across European venues suggest that the positive reaction to the latest guidance reaffirmation and the anticipation of November news is not confined to the primary Copenhagen quotation.
Nine-month 2026 figures and fiscal 2025/26 guidance
The fundamental backdrop to the current move in Coloplast stock is the company’s nine-month 2026 performance and its reiterated outlook for fiscal 2025/26. A detailed financial overview dated August 24, 2026, notes that Coloplast held a nine-month 2026 earnings call on August 18, 2026 and on the same date confirmed its earnings targets for the 2025/26 fiscal year. The overview groups Coloplast’s 2026 and 2027 figures alongside historical numbers, showing projected revenue of 30.78 billion units for 2027 compared with 28.84 billion units for 2026, and projected net income of 5.84 billion units for 2027 versus 3.79 billion units for 2026. Taken at face value, these figures indicate that analysts expect Coloplast’s top line to grow by 1.94 billion units between 2026 and 2027, and net profit to increase by 2.05 billion units over the same period, reflecting a view that the company can sustain mid-single-digit revenue growth and more pronounced earnings expansion as it executes on its strategy.
Within the same overview, nine-month 2026 segment data and multi-year comparisons highlight how Coloplast has been building earnings power. For example, one line shows revenue rising from 3.61 billion units in a historical year to 3.85 billion units in 2027 projections, with net income over a comparable horizon moving from 475 million units to 731 million units. Another set of figures places revenue at 6.28 billion units in 2026 and 6.71 billion units in 2027, while net income is expected to grow from 826 million units to 1.27 billion units in those respective years. Though the units in the table are not explicitly labeled, the structural pattern is clear: analysts foresee revenue increases of 6-7% across key product and geographic segments, with net income growing faster than sales, implying margin expansion as Coloplast scales its chronic-care offerings and continues to optimize manufacturing and logistics.
These projections fit with Coloplast’s decision on August 18, 2026 to reiterate its earnings guidance for fiscal 2025/26 rather than adjust it. The guidance confirmation indicates that management remains confident in its ability to deliver the planned growth and profitability improvements despite macroeconomic uncertainties and competitive pressures in the global medtech market. The nine-month 2026 earnings call therefore acts as a bridge between the current fiscal year and the November guidance event that analysts expect to define the trajectory for 2026/27 and beyond.
Valuation, consensus view and ETF exposure
Consensus data from the same August 24, 2026 financial portal shows that Coloplast stock currently carries a hold-type average recommendation across 20 covering analysts, with an average target price of 467.10DKK against a last closing price of 438.60DKK. That gap of 28.50DKK represents potential upside of 6.50% if the consensus view proves accurate. Meanwhile, at least one more optimistic analyst maintains a target of 530DKK, implying an upside of 91.40DKK or around 20.8% relative to the latest close. This divergence between the average target and the highest published target underlines that while some market participants see Coloplast as fairly valued on near-term metrics, others think the stock could rerate meaningfully if November guidance confirms stronger growth or margin trajectories.
Coloplast’s presence in exchange-traded products further embeds the stock in institutional portfolios. A dedicated ETF overview updated on August 24, 2026 notes that Coloplast A/S Class B shares close at 460.30DKK, up 26.60DKK or 6.15% at 12:05 GMT-4, within a basket of funds that hold the stock as part of broader healthcare and medtech allocations. The table lists multiple ETFs with varying market values and weights, showing that Coloplast’s inclusion provides investors with diversified exposure to chronic-care devices and ostomy products. For investors who own such ETFs, the recent 6.15% single-session gain in Coloplast’s ETF-referenced price means that the stock is currently a positive contributor to fund performance, even if its longer-term year-to-date profile is still negative when measured against the start-of-year level.
From a valuation perspective, if Coloplast were to trade at the average target price of 467.10DKK, the move from 438.60DKK would represent a gain of 6.50%, whereas reaching the 530DKK optimistic target would require a more pronounced rally of 20.8%. In that context, the recent real-time figures around 456.55DKK show the shares trading between these two reference points, suggesting that the market is partially pricing in some of the anticipated November guidance upside but has not fully embraced the most bullish scenarios yet.
Chronic care products underpin the long-term story
Behind the numbers, Coloplast’s business revolves around products for people with intimate healthcare needs, particularly ostomy care, continence care and wound and skin care. A representative product category is ostomy bags and accessories, where the company offers a range of pouches, barrier rings, and supporting devices designed to help patients manage stoma output comfortably and discreetly. These products are typically reimbursed within healthcare systems and often used on a recurring basis, creating a stable demand pattern that can support Coloplast’s revenue and cash flow growth over many years.
In continence care, Coloplast supplies intermittent catheters and related devices that enable individuals with urinary retention or neurological conditions to safely empty their bladder. As populations age and the prevalence of chronic conditions rises, demand for such solutions tends to grow. When combined with Coloplast’s wound and skin care offerings, including advanced dressings and creams that help protect fragile skin and promote healing, these product lines form a cohesive chronic-care portfolio aimed at improving patients’ quality of life. For investors, the key question is how effectively Coloplast can translate this strong product positioning into sustained revenue growth and margin expansion, particularly in light of the nine-month 2026 projections that show net income growing faster than sales.
Coloplast stock and trading venue context
Coloplast A/S is primarily listed on Nasdaq Copenhagen, where its Class B shares trade in Danish kroner and form part of regional healthcare and medtech indices. The real-time and delayed data snapshots from August 24, 2026 show that the primary and secondary quotations are aligned, with the Copenhagen closing price of 438.60DKK being echoed in analyst tables and the ETF-focused overview capturing a subsequent close at 460.30DKK after a strong session. The euro-denominated prices on Xetra, Tradegate and Frankfurt, around the 60.60EUR to 60.94EUR range, reflect currency translation and local liquidity conditions but ultimately track the Copenhagen line.
As of August 24, 2026, Coloplast stock’s recent dynamics can be summarized as follows: a prior close of 438.60DKK, real-time intraday indications in the mid-450DKK area with a 4.09% gain over five days, a year-to-date performance showing a decline of more than 16%, and ETF-linked pricing at 460.30DKK after a 6.15% daily rise. Against that backdrop, consensus targets around 467.10DKK and a highest cited target of 530DKK frame the debate on valuation. The near-term narrative now hinges on how Coloplast’s November guidance update will interact with these expectations and whether the company’s chronic-care portfolio and nine-month 2026 performance will justify a rerating of the shares.
Read more
Ostomy care solutions as a flagship line
Among Coloplast’s many product lines, ostomy care solutions stand out as a flagship business that underpins both its financial performance and its reputation in the healthcare community. Ostomy surgery, which creates a stoma for patients with certain gastrointestinal or urinary conditions, requires reliable, comfortable, and discreet appliances to collect bodily output. Coloplast provides one-piece and two-piece ostomy bags, baseplates, barrier rings, and supporting accessories that are designed to minimize leakage, protect the skin around the stoma, and allow patients to lead active lives.
Coloplast’s focus on innovation in ostomy care, such as improved adhesive technologies and more flexible materials, has helped the company maintain strong positions in key markets across Europe and beyond. The recurring nature of ostomy product usage, with patients typically needing multiple bags and accessories per week, creates a steady revenue stream that complements the more cyclical elements of medtech demand. In the nine-month 2026 projections, the increasing revenue and net income figures across segments likely reflect ongoing growth in such chronic-care categories, where Coloplast’s differentiated products and clinical relationships can translate into market share gains and pricing power.
Shares align with ETF and analyst context
Looking ahead from August 24, 2026, Coloplast stock sits at the intersection of several forces: the reaffirmed fiscal 2025/26 guidance backed by nine-month 2026 data, the consensus view that sees mid-single-digit upside to the average target price, the presence of a more bullish 530DKK target suggesting room for a stronger rerating, and the practical reality of ETF allocations that amplify the stock’s moves across diversified portfolios. If the November guidance update confirms that revenue can grow from 28.84 billion units in 2026 to 30.78 billion units in 2027 and net income can rise from 3.79 billion units to 5.84 billion units as projected, investors may reassess Coloplast’s valuation relative to broader medtech peers.
For now, the numbers are clear: Coloplast’s last recorded close at 438.60DKK, its ETF-linked close at 460.30DKK after a 6.15% daily gain, real-time trading indications around 456.55DKK with a 4.09% five-day rise and a 7.95% gain since the start of 2026, and consensus targets that sit 6.50% above the last close with individual upside scenarios of more than 20%. The November guidance event, flagged by analyst coverage as the next catalyst, will determine whether these figures represent a plateau or a launch point for the next phase in Coloplast stock’s journey.
Fact box
Company: Coloplast A/S
ISIN: DK0060448595
Ticker: COLO B
Exchange: Nasdaq Copenhagen
Price (as of August 24, 2026, 12:05 p.m. local time): 460.30DKK
Market cap: not specified in the cited sources
Sector / Industry: Healthcare - Medical technology and chronic care
Index membership: regional healthcare and medtech indices
